Neuspera Overview
- Year Founded
-
2013
- Status
-
Private
- Employees
-
38
- Latest Deal Type
-
Series D
- Latest Deal Amount
-
$24.2M
- Investors
-
19
Neuspera General Information
Description
Developer of implantable neurostimulation medical device systems intended for treating chronic conditions such as urinary urge incontinence and peripheral nerve-related disorders. The company's platform utilizes ultra-miniaturized, wirelessly powered implants combined with external wearable transmitters, delivers targeted neuromodulation therapy through devices implanted near nerves, supports communication and control via clinician programming interfaces, incorporates battery-free or externally powered designs to reduce surgical complexity and complications, enables minimally invasive implantation procedures, and provides adaptive energy transfer technology for deep-tissue operation, enabling patients and healthcare providers to access less invasive, flexible, and functionally efficient treatment alternatives.
Contact Information
Website
www.neuspera.comCorporate Office
- 51 Daggett Drive
- San Jose, CA 95134
- United States
Corporate Office
- 51 Daggett Drive
- San Jose, CA 95134
- United States
Neuspera Timeline
Neuspera Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 7. Later Stage VC (Series D) | 18-Jun-2024 | $24.2M | Completed | Generating Revenue | ||
| 6. Accelerator/Incubator | 29-May-2024 | Completed | Generating Revenue | |||
| 5. Later Stage VC (Series CC) | 01-Sep-2022 | Completed | Generating Revenue | |||
| 4. Later Stage VC (Series C) | 09-Jun-2021 | Completed | Generating Revenue | |||
| 3. Later Stage VC (Series B) | 17-Jan-2018 | Completed | Generating Revenue | |||
| 2. Early Stage VC (Series A) | 26-Apr-2016 | $8.89M | $8.89M | Completed | Startup | |
| 1. University Spin-Out | 03-Dec-2013 | Completed | Startup |
Neuspera Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price | % Owned |
|---|---|---|---|---|---|---|---|---|
| Series DD | ||||||||
| Series D | ||||||||
| Series CC | ||||||||
| Series C-1 | ||||||||
| Series C | ||||||||
| Series B | 2,187,574 | $0.010000 | 8% | $8.11 | $8.11 | 1x | $5.51 | 4.92% |
| Series A | 1,409,412 | $0.010000 | 8% | $6.31 | $6.31 | 1x | $4.93 | 2.75% |
VC Exit Predictor
See how our proprietary methodology utilizes historical data sets to synthesize the likelihood of an acquisition, IPO, or no exit event. Get a detailed look at the calculations behind our predictions.
Neuspera Comparisons
Industry
Financing
Details
Neuspera Competitors (48)
One of Neuspera’s 48 competitors is Cala Health, a Venture Capital-Backed company based in San Mateo, CA.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Cala Health | Venture Capital-Backed | San Mateo, CA | ||||
| ShiraTronics | Venture Capital-Backed | Minneapolis, MN | ||||
| Neuromonics | Formerly VC-backed | Calabasas, CA | ||||
| Advanced Bionics | Formerly VC-backed | Valencia, CA | ||||
| Curonix | Private Equity-Backed | Pompano Beach, FL |
Neuspera Patents
Neuspera Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| US-20250288816-A1 | Trialing system for sacral neuromodulation therapy | Pending | 14-Mar-2024 | ||
| WO-2025064816-A1 | Midfield transmitter polarization techniques | Inactive | 20-Sep-2023 | ||
| AU-2021342061-A1 | Implantable device fixation mechanisms | Active | 08-Sep-2020 | ||
| AU-2021342061-B2 | Implantable device fixation mechanisms | Active | 08-Sep-2020 | ||
| EP-4210810-A1 | Implantable device fixation mechanisms | Pending | 08-Sep-2020 | A61N1/37518 |
Neuspera Signals
Neuspera Investors (19)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| 120 Capital | Venture Capital | Minority | ||
| Cerity Partners Ventures | Corporate Venture Capital | Minority | ||
| Foreground Capital | Venture Capital | Minority | ||
| Olympus Innovation Ventures | Corporate Venture Capital | Minority | ||
| Revelation Partners | Venture Capital | Minority |
Neuspera FAQs
-
When was Neuspera founded?
Neuspera was founded in 2013.
-
Where is Neuspera headquartered?
Neuspera is headquartered in San Jose, CA.
-
What is the size of Neuspera?
Neuspera has 38 total employees.
-
What industry is Neuspera in?
Neuspera’s primary industry is Therapeutic Devices.
-
Is Neuspera a private or public company?
Neuspera is a Private company.
-
What is the current valuation of Neuspera?
The current valuation of Neuspera is .
-
What is Neuspera’s current revenue?
The current revenue for Neuspera is .
-
How much funding has Neuspera raised over time?
Neuspera has raised $128M.
-
Who are Neuspera’s investors?
120 Capital, Cerity Partners Ventures, Foreground Capital, Olympus Innovation Ventures, and Revelation Partners are 5 of 19 investors who have invested in Neuspera.
-
Who are Neuspera’s competitors?
Cala Health, ShiraTronics, Neuromonics, Advanced Bionics, and Curonix are some of the 48 competitors of Neuspera.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process